| Ai-mae Chee Watkins, MD | |
|
11370 Anderson St, Ste 3900, Loma Linda, CA 92354-3450 | |
| (909) 558-2806 | |
| Not Available |
| Full Name | Ai-mae Chee Watkins |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 31 Years |
| Location | 11370 Anderson St, Loma Linda, California |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114031663 | NPI | - | NPPES |
| 00G807070 | Medicaid | CA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | G80707 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Loma Linda University Medical Center | Loma linda, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Faculty Physicians And Surgeons Of Llusm | 1153227814 | 1053 |
News Archive
Boston Therapeutics, Inc. has announced that it has submitted structure and function claims of its SUGARDOWN™ to the US Food and Drug Administration on June 21, 2010.
Castration-resistant prostate cancer (CRPC), defined as tumor progression despite castrate levels of testosterone, develops in many prostate cancer patients treated with androgen-deprivation therapy. Current treatment regimens are complicated by toxicities and a low rate of relapse-free survival. Many novel therapies in clinical trials offer hope for patients with this challenging diagnosis. Healthcare professionals who are treating CRPC must stay abreast of these emerging therapies to ensure optimal care for these patients.
The decision to not resume warfarin therapy following a gastrointestinal bleeding event is linked to an increased risk for thrombosis and mortality, researchers suggest.
In a new Phase III study, BRINAVESSTM (vernakalant) intravenous, an investigational compound being developed in the European Union by Merck (known as MSD outside the USA and Canada) and Cardiome Pharma Corp. to treat atrial fibrillation, showed that BRINAVESS was superior to amiodarone injection, in converting patients' heart rate from atrial fibrillation (AF) to sinus rhythm (SR) within 90 minutes of the start of administration.
Johns Hopkins researchers have uncovered strong evidence that mice have a specific set of nerve cells that signal itch but not pain, a finding that may settle a decades-long debate about these sensations, and, if confirmed in humans, help in developing treatments for chronic itch, including itch caused by life-saving medications.
› Verified 8 days ago
| Entity Name | Faculty Physicians And Surgeons Of Llusm |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205009917 PECOS PAC ID: 1153227814 Enrollment ID: O20031211000981 |
News Archive
Boston Therapeutics, Inc. has announced that it has submitted structure and function claims of its SUGARDOWN™ to the US Food and Drug Administration on June 21, 2010.
Castration-resistant prostate cancer (CRPC), defined as tumor progression despite castrate levels of testosterone, develops in many prostate cancer patients treated with androgen-deprivation therapy. Current treatment regimens are complicated by toxicities and a low rate of relapse-free survival. Many novel therapies in clinical trials offer hope for patients with this challenging diagnosis. Healthcare professionals who are treating CRPC must stay abreast of these emerging therapies to ensure optimal care for these patients.
The decision to not resume warfarin therapy following a gastrointestinal bleeding event is linked to an increased risk for thrombosis and mortality, researchers suggest.
In a new Phase III study, BRINAVESSTM (vernakalant) intravenous, an investigational compound being developed in the European Union by Merck (known as MSD outside the USA and Canada) and Cardiome Pharma Corp. to treat atrial fibrillation, showed that BRINAVESS was superior to amiodarone injection, in converting patients' heart rate from atrial fibrillation (AF) to sinus rhythm (SR) within 90 minutes of the start of administration.
Johns Hopkins researchers have uncovered strong evidence that mice have a specific set of nerve cells that signal itch but not pain, a finding that may settle a decades-long debate about these sensations, and, if confirmed in humans, help in developing treatments for chronic itch, including itch caused by life-saving medications.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ai-mae Chee Watkins, MD 54701 File Number, Los Angeles, CA 90074-4701 Ph: (909) 558-3111 | Ai-mae Chee Watkins, MD 11370 Anderson St, Ste 3900, Loma Linda, CA 92354-3450 Ph: (909) 558-2806 |
News Archive
Boston Therapeutics, Inc. has announced that it has submitted structure and function claims of its SUGARDOWN™ to the US Food and Drug Administration on June 21, 2010.
Castration-resistant prostate cancer (CRPC), defined as tumor progression despite castrate levels of testosterone, develops in many prostate cancer patients treated with androgen-deprivation therapy. Current treatment regimens are complicated by toxicities and a low rate of relapse-free survival. Many novel therapies in clinical trials offer hope for patients with this challenging diagnosis. Healthcare professionals who are treating CRPC must stay abreast of these emerging therapies to ensure optimal care for these patients.
The decision to not resume warfarin therapy following a gastrointestinal bleeding event is linked to an increased risk for thrombosis and mortality, researchers suggest.
In a new Phase III study, BRINAVESSTM (vernakalant) intravenous, an investigational compound being developed in the European Union by Merck (known as MSD outside the USA and Canada) and Cardiome Pharma Corp. to treat atrial fibrillation, showed that BRINAVESS was superior to amiodarone injection, in converting patients' heart rate from atrial fibrillation (AF) to sinus rhythm (SR) within 90 minutes of the start of administration.
Johns Hopkins researchers have uncovered strong evidence that mice have a specific set of nerve cells that signal itch but not pain, a finding that may settle a decades-long debate about these sensations, and, if confirmed in humans, help in developing treatments for chronic itch, including itch caused by life-saving medications.
› Verified 8 days ago
Samira Monavvari, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 11370 Anderson St Ste 3900, Loma Linda, CA 92354 Phone: 909-558-2806 | |
Danielle C.a. Sawyer-macknet, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 25805 Barton Rd, Suite 107, Loma Linda, CA 92354 Phone: 909-478-7700 Fax: 909-478-7705 | |
Dr. Tiare Nicole Evans, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 11370 Anderson St Ste 3900, Loma Linda, CA 92354 Phone: 909-558-2806 | |
Kevin C Balli, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 11370 Anderson St, Ste 3900, Loma Linda, CA 92354 Phone: 909-558-2806 | |
Juthamas Kositsawat, Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 11370 Anderson St, Loma Linda, CA 92354 Phone: 909-558-2806 | |
Hermina Salvador, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 11370 Anderson St, Ste 3900, Loma Linda, CA 92354 Phone: 909-558-2806 |